Premium
Topical gentian violet for cutaneous infection and nasal carriage with MRSA
Author(s) -
Okano Masaki,
Noguchi Sanai,
Tabata Koshi,
Matsumoto Yasutaka
Publication year - 2000
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1046/j.1365-4362.2000.00128.x
Subject(s) - medicine , staphylococcus aureus , carriage , dermatology , skin infection , microbiology and biotechnology , nose , surgery , bacteria , pathology , biology , genetics
This study describes a potential effect of topical gentian violet on cutaneous infection and nasal carriage with methicillin‐resistant Staphylococcus aureus (MRSA). 0.5% gentian violet was used in 28 cases of skin lesions once a day, while a 0.3% solution was applied on the nasal vestibules of nine cases twice a day. The period for eradication in the 28 skin cases was 9.1 ± 6.0 days. It was 15.3 ± 9.0 days for the nine nasal lesions. The minimal inhibitory concentration (MIC) of gentian violet against MRSA from the four isolated strains was 0.0225 ± 0.0096 μg/mL. No adverse reactions occurred throughout the study. It is suggested that gentian violet may be potentially effective against MRSA.